Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 6/20 | 0.65 |
| ▸ | CES1 | P23141 | 6/20 | 0.65 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL29155469 | 0.81 | CES2 (0.61) | CES2CES1HCAR1CA1CA12 | |
| SCHEMBL4470662 | 0.79 | CES2 (0.68) | CES2CES1HCAR1CA1CA12 | |
| SCHEMBL2156965 | 0.79 | CES2 (1.00) | CES2CES1HCAR1CA1CA12 | |
| SCHEMBL157714 | 0.77 | HCAR1 (0.73) | CES2CES1HCAR1CA1CA12 | |
| SCHEMBL9693658 | 0.77 | CES2 (0.65) | CES2CES1HCAR1CA1CA12 | |
| SCHEMBL12648828 | 0.74 | CES2 (0.62) | CES2CES1HCAR1CA1CA12 | |
| SCHEMBL349065 | 0.74 | CES2 (0.62) | CES2CES1HCAR1CA1CA12 | |
| SCHEMBL2093012 | 0.74 | CES2 (0.62) | CES2CES1HCAR1CA1CA12 | |
| Hydrochloric Acid SCHEMBL6518491 | 0.74 | HCAR1 (0.70) | CES2CES1HCAR1CA1CA12 | |
| SCHEMBL114867 | 0.74 | CES2 (0.62) | CES2CES1HCAR1CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030036661-A1 | 2-Aroyl-4-acyl paclitaxel (taxol) analogs | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-20 | — | — | US | claimed |
| EP-1067923-A4 | 2-AROYL-4-ACYL PACLITAXEL (TAXOL) ANALOGS | BRISTOL MYERS SQUIBB CO (US) | 2002-11-13 | — | — | EP | claimed |
| EP-1067923-A1 | 2-AROYL-4-ACYL PACLITAXEL (TAXOL) ANALOGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999033462-A9 | 2-AROYL-4-ACYL PACLITAXEL (TAXOL) ANALOGS | KINGSTON DAVID GEORGE IAN (US) | 1999-09-30 | — | — | WO | claimed |
| WO-1999033462-A1 | 2-AROYL-4-ACYL PACLITAXEL (TAXOL) ANALOGS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 1999-07-08 | — | — | WO | claimed |
| US-20030036661-A1 | 2-Aroyl-4-acyl paclitaxel (taxol) analogs | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-20 | — | — | US | disclosed |
| EP-1067923-A4 | 2-AROYL-4-ACYL PACLITAXEL (TAXOL) ANALOGS | BRISTOL MYERS SQUIBB CO (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6476242-B1 | 2-aroyl-4-acyl paclitaxel (Taxol) analogs | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| EP-1067923-A1 | 2-AROYL-4-ACYL PACLITAXEL (TAXOL) ANALOGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999033462-A9 | 2-AROYL-4-ACYL PACLITAXEL (TAXOL) ANALOGS | KINGSTON DAVID GEORGE IAN (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999033462-A1 | 2-AROYL-4-ACYL PACLITAXEL (TAXOL) ANALOGS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036661-A1 | 2-Aroyl-4-acyl paclitaxel (taxol) analogs | HDAC6, HDAC3, ACAT2 | CES2 1248/4885CES1 2543/4885HCAR1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.